Author's response to reviews

Title: Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs AEZS 108 and AEZS 125

Authors:

Stephan Seitz (seitzs@caritasstjosef.de)
Stefan Buchholtz (sbuchholtz@caritasstjosef.de)
Andrew V Schally (avschally@va.gov)
Florian Weber (florian.weber@ukr.de)
Monika Klinkhammer-Schalke (zentrum.tumor@klinik.uni-regensburg.de)
Elisabeth C Inwald (einwald@caritasstjosef.de)
Roberto Perez (robert.perez.phd@gmail.com)
Ferenc G Rick (Frick@med.miami.edu)
Luca Szalontay (Lszalontay@miami.edu)
Florian Hohla (f.hohla@salk.at)
Sabine Segerer (ssegerer@endokrinologikum.de)
Chiu-Wai Kwok (babsckw@hotmail.com)
Olaf Ortmann (ortmann@caritasstjosef.de)
Jörg B Engel (joergbengel@hotmail.com)

Version: 5
Date: 19 August 2014

Author's response to reviews:

Dear editors,

the typographical errors were corrected and the paragraphs on ethical guidelines and informed consent were extended and now read as follows:

"The Institutional Animal Care and Use Committee (Medical Research Service of the Veterans Affairs Department) reviewed the protocol for the animal experiments and gave full approval. All the procedures in vivo were in accordance with UKCCCR guidelines for the welfare of animals in experimental neoplasia."

"Tumor samples and data were collected at the Tumor Center Regensburg a high quality population-based regional cancer registry covering a population of more than 2.2 million people of the districts of Upper Palatinate and Lower Bavaria and the University of Regensburg (Department of Gynecology and Obstetrics, Department of Pathology) following institutional guidelines and approval from the ethics committee of the University of Regensburg. Written informed consent for sample collection was obtained from all patients."

The correct email address was provided for all authors.

We hope the MS now meets the standard of your journal.
Yours sincerely
JörgEngel, MD